Daver, N., Lee, K. H., Choi, Y., Montesinos, P., Jonas, B. A., Arellano, M. L., … Bejar, R. (2024). Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML. In Blood (Vol. 144, pp. 4255–4255). American Society of Hematology. https://doi.org/10.1182/blood-2024-200397

Daver, Naval, Kyoo Hyung Lee, Yunsuk Choi, Pau Montesinos, Brian A. Jonas, Martha L. Arellano, Uma Borate, et al. “Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML.” In Blood, 144:4255–4255. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-200397.

Daver N, Lee KH, Choi Y, Montesinos P, Jonas BA, Arellano ML, et al. Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML. In: Blood. American Society of Hematology; 2024. p. 4255–4255.

Daver, Naval, et al. “Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 4255–4255. Crossref, doi:10.1182/blood-2024-200397.

Daver N, Lee KH, Choi Y, Montesinos P, Jonas BA, Arellano ML, Borate U, Watts JM, Koller PB, Jung CW, Sohn SK, Fathi AT, Vachhani P, Podoltsev NA, Salamero O, Yoon S-S, Lee J-O, Mannis GN, Tan S, Mukherjee S, Erba H, Shin H-J, Platzbecker U, Tormo M, Tam E, Berkahn L, Bernal T, Haney DN, Hu J, Sinha RK, Khan N, Victory VC, Rice WG, Bejar R. Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML. Blood. American Society of Hematology; 2024. p. 4255–4255.